Skip to main content

ipilimumab (Yervoy®)

 

Status: Excluded due to NICE appraisal

Product meets AWMSG exclusion criteria due to NICE appraisal TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma in adults

Medicine details

Medicine name ipilimumab (Yervoy®)
Formulation 5 mg/ml concentrate for solution for infusion
Reference number 1293
Indication

Treatment of advanced (unresectable or metastatic) melanoma in adults who have not received prior therapy

Company Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter Malignant disease & immunosuppression
Submission type N/A
Status Excluded due to NICE appraisal
Date of issue 31/10/2013
NICE guidance

TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma in adults